| P50 | author | Carsten A. Wagner | Q57045232 |
| P2093 | author name string | Max Gassmann | |
| | Udo Schnitzbauer | |
| | Carla Bettoni | |
| | Arezoo Daryadel | |
| | Luciano Natale | |
| | Petra Seebeck | |
| P2860 | cites work | Bone tissue as a systemic endocrine regulator | Q26825306 |
| | Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism | Q30544587 |
| | Klotho up-regulates renal calcium channel transient receptor potential vanilloid 5 (TRPV5) by intra- and extracellular N-glycosylation-dependent mechanisms | Q34774466 |
| | A method for isolating high quality RNA from mouse cortical and cancellous bone | Q34802787 |
| | Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly. | Q35141350 |
| | Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin | Q35328384 |
| | Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. | Q35558693 |
| | Colocalization of the (Pro)renin Receptor/Atp6ap2 with H+-ATPases in Mouse Kidney but Prorenin Does Not Acutely Regulate Intercalated Cell H+-ATPase Activity | Q35908500 |
| | Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1 | Q36775194 |
| | The role of transient receptor potential channels in kidney disease | Q37527790 |
| | FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis | Q37683399 |
| | Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models | Q37833828 |
| | High altitude renal syndrome (HARS). | Q37874865 |
| | New Treatment Approaches for the Anemia of CKD. | Q38587175 |
| | Erythropoietin in bone - Controversies and consensus | Q38715454 |
| | FGF23-αKlotho as a paradigm for a kidney-bone network | Q39009569 |
| | Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells | Q39847928 |
| | The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel | Q40359636 |
| | Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide-induced inflammation. | Q40478704 |
| | Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease. | Q41108018 |
| | The intestinal phosphate transporter NaPi-IIb (Slc34a2) is required to protect bone during dietary phosphate restriction | Q41477711 |
| | Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow | Q45109843 |
| | Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. | Q45911764 |
| | Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice. | Q46221935 |
| | FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase | Q47099652 |
| | Erythropoietin directly stimulates osteoclast precursors and induces bone loss | Q47441831 |
| | Excessive erythrocytosis in adult mice overexpressing erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration | Q48544000 |
| | α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling | Q50001744 |
| | Acute blood loss stimulates fibroblast growth factor 23 production. | Q50197535 |
| | Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury | Q50209133 |
| | Coordinated regulation of TRPV5-mediated Ca²⁺ transport in primary distal convolution cultures. | Q50460870 |
| | Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. | Q52685153 |
| | Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. | Q53074041 |
| | Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity | Q57109221 |
| | The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk | Q57314982 |
| | Expression of Na-P(i) cotransport in rat kidney: localization by RT-PCR and immunohistochemistry | Q71626282 |
| | Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin | Q73387927 |
| | Abortion in mice with excessive erythrocytosis is due to impaired arteriogenesis of the uterine arcade | Q80650182 |
| | Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury | Q83176720 |
| | Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study | Q85370116 |
| | Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease | Q88265833 |
| | Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men | Q89370041 |
| | Expression and localization of fibroblast growth factor (FGF)23 and Klotho in the spleen: its physiological and functional implications | Q89950540 |
| | Effects of erythropoietin on fibroblast growth factor 23 in mice and humans | Q90209853 |
| P433 | issue | 1 | |
| P304 | page(s) | 14989 | |
| P577 | publication date | 2019-10-18 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Elevated FGF23 and disordered renal mineral handling with reduced bone mineralization in chronically erythropoietin over-expressing transgenic mice | |
| P478 | volume | 9 | |